Cardio-embolic stroke: Lessons from a single centre in Sub-Saharan Africa.


Journal

Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 19 07 2018
revised: 05 01 2019
accepted: 13 02 2019
pubmed: 4 6 2019
medline: 1 5 2020
entrez: 4 6 2019
Statut: ppublish

Résumé

Limited information is available about cardio-embolic stroke (CES) in sub-Saharan Africa. The aim of this study was to describe the epidemiology, clinical features, etiology, the management and outcome of CES in our setting. A retrospective cohort study was carried out in the Douala General Hospital (DGH), using files of ischemic stroke patients admitted in the Neurological Unit and the Intensive Care Unit. Socio-demographic, clinical and paraclinical data were collected. After hospitalization, follow-up was performed with focus on mortality, stroke recurrence and the functional outcome assessed with Barthel score. Multivariate analysis was performed to determine the factors associated with death. Of the 704 stroke cases included, 368 were ischemic with 86 (23.4%) of them being cardio-embolic. The mean age of patient with CES was 67±13.3 years. The main etiologies of CES were: atrial fibrillation (82.1%), dilated cardiomyopathy (12.8%), and rheumatic mitral stenosis (5.1%). Anti-platelet agents were the most prescribed anti-thrombotic drugs (50.7%). The in-hospital mortality rate was 23.3% with lesion in both internal carotid arteries [OR=110.3; 95% CI: 1.2-1040.7; P=0.043] and heart disease [OR=46.9; 95% CI: 1.2-1789.9; P=0.038] appeared to be predictive of this. Stroke recurrence was observed in 8 patients (12.1%) and the survival probability in 5 years was 10%. Functional outcome was progressively worse with the systolic blood pressure>140mmHg (P=0.025) been the associated factor. CES accounted for 1/4 of ischemic stroke with a high risk of early death and long-term recurrence. Atrial fibrillation was the leading cause of CES. The association of VKA and anti-platelet agent should be avoided to reduce early death during acute stroke.

Sections du résumé

BACKGROUND BACKGROUND
Limited information is available about cardio-embolic stroke (CES) in sub-Saharan Africa. The aim of this study was to describe the epidemiology, clinical features, etiology, the management and outcome of CES in our setting.
METHODS METHODS
A retrospective cohort study was carried out in the Douala General Hospital (DGH), using files of ischemic stroke patients admitted in the Neurological Unit and the Intensive Care Unit. Socio-demographic, clinical and paraclinical data were collected. After hospitalization, follow-up was performed with focus on mortality, stroke recurrence and the functional outcome assessed with Barthel score. Multivariate analysis was performed to determine the factors associated with death.
RESULTS RESULTS
Of the 704 stroke cases included, 368 were ischemic with 86 (23.4%) of them being cardio-embolic. The mean age of patient with CES was 67±13.3 years. The main etiologies of CES were: atrial fibrillation (82.1%), dilated cardiomyopathy (12.8%), and rheumatic mitral stenosis (5.1%). Anti-platelet agents were the most prescribed anti-thrombotic drugs (50.7%). The in-hospital mortality rate was 23.3% with lesion in both internal carotid arteries [OR=110.3; 95% CI: 1.2-1040.7; P=0.043] and heart disease [OR=46.9; 95% CI: 1.2-1789.9; P=0.038] appeared to be predictive of this. Stroke recurrence was observed in 8 patients (12.1%) and the survival probability in 5 years was 10%. Functional outcome was progressively worse with the systolic blood pressure>140mmHg (P=0.025) been the associated factor.
CONCLUSION CONCLUSIONS
CES accounted for 1/4 of ischemic stroke with a high risk of early death and long-term recurrence. Atrial fibrillation was the leading cause of CES. The association of VKA and anti-platelet agent should be avoided to reduce early death during acute stroke.

Identifiants

pubmed: 31155304
pii: S0035-3787(18)30759-8
doi: 10.1016/j.neurol.2019.02.004
pii:
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

544-551

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Y N Mapoure (YN)

Department of Clinical Sciences, Faculty of medicine and pharmaceutical sciences, University of Douala, Douala General Hospital, 25019 Douala, Cameroon; Douala General Hospital, Douala, Cameroon. Electronic address: mapoureyacouba@gmail.com.

F Kamdem (F)

Department of Clinical Sciences, Faculty of medicine and pharmaceutical sciences, University of Douala, Douala General Hospital, 25019 Douala, Cameroon; Douala General Hospital, Douala, Cameroon. Electronic address: kamdem_djimegne@yahoo.fr.

F J Akeyeh (FJ)

Department of Clinical Sciences, Faculty of medicine and pharmaceutical sciences, University of Douala, Douala General Hospital, 25019 Douala, Cameroon. Electronic address: neodelacruz747@yahoo.fr.

A Dzudie (A)

Department of Clinical Sciences, Faculty of medicine and pharmaceutical sciences, University of Douala, Douala General Hospital, 25019 Douala, Cameroon; Department of Physiology, University of Yaoundé I, Douala, Cameroon. Electronic address: aitdzudie@yahoo.com.

S Mouliom (S)

Department of Clinical Sciences, Faculty of medicine and pharmaceutical sciences, University of Douala, Douala General Hospital, 25019 Douala, Cameroon; Douala General Hospital, Douala, Cameroon. Electronic address: masidick@yahoo.fr.

A S Mouelle (AS)

Department of Clinical Sciences, Faculty of medicine and pharmaceutical sciences, University of Douala, Douala General Hospital, 25019 Douala, Cameroon; Douala General Hospital, Douala, Cameroon. Electronic address: albert.mouelle@yahoo.fr.

H N Luma (HN)

Douala General Hospital, Douala, Cameroon; Department of Internal Medicine, University of Yaoundé I, Douala, Cameroon. Electronic address: hnluma@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH